Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

OBJECTIVE: In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA(1c)], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes Care
Auteurs principaux: Jabbour, Serge A., Frías, Juan P., Ahmed, Azazuddin, Hardy, Elise, Choi, Jasmine, Sjöström, C. David, Guja, Cristian
Format: Artigo
Langue:Inglês
Publié: American Diabetes Association 2020
Sujets:
Emerging Therapies: Drugs and Regimens
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7510043/
https://ncbi.nlm.nih.gov/pubmed/32816874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc19-1350
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires